Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Stock Report

| More

Bal Pharma poised to strengthen its position in diabetes segment through its API Gliclazide

Posted On: 2021-09-28 14:36:17 (Time Zone: IST)

Bal Pharma, a fully integrated pharmaceutical Company specialized in Prescription Drugs, Generics, pharma intermediates and Bulk Actives is further strengthening its market leading position in Active Pharmaceutical ingredient (API) Gliclazide with higher capacity utilization at the existing facility, and the streamlining of new facility that commenced production of Gliclazide in September, 2020.

Bal Pharma is one of the largest producers and exporters of an API Gliclazide, which is used to treat type 2 diabetes. The company has a total capacity to manufacture 17.5 MT Gliclazide per month. One of the manufacturing facilities located at Bommasandra, Bangalore, with the capacity of 7.5 MT per month, its capacity utilization dip to 60% due to Covid related lockdown, which bounced back to 85% utilization level in FY2021. The second unit with a manufacturing capacity of Glicalzide of 10 MT per month is located at Udaipur , Rajasthan which has started production in September , 2020. This new facility operated at 35% utilization during FY2021 which has now stabilized and has been operating at 45% during the first five months of FY2022. With improved utilization, Bal Pharma is further strengthening its market leading position in Gliclazide. The Company expects to achieve an average utilization of 70% of its Gliclazide capacity in FY2022.

Gliclazide, API is a sulfonyl urea component used for treating type 2 Diabetes, has been an important contributor in the company's earnings. In terms of volume, Bal Pharma controls over 25% of the world's Gliclazide market of 415 tonnes as per IQVIA report and is growing at the rate of 5% per annum. Company also captively consumes its Gliclazide for manufacturing formulations. Its Domestic formulations are sold under the brand name DIABEND. The Company generated about 44 % of its total revenues from Gliclazide in FY2021. Company generated %100 crores of revenue in FY21 from Gliclazide (API+ Formulations) Although, the company has increased focus on marketing the other products aggressively, Bal Pharma's API revenues are likely to be substantially contributed by gliclazide in the medium term given the time lag expected in ramp up of new products.

Bal Pharma Gliclazide API exports footprint covers more than 35 countries across the world. The Company is targeting to further expand geographic presence in Gliclazide and has supplied samples to new customers. Domestic market for Gliclazide (API + Formulations) is close to 60% of overall sales of Gliclazide for FY21.

Besides improving the market share, Bal Pharma is also committed to reduce import dependency for Gliclazide raw material N-Aminio Azabicyclo octane (3,3,0) hydrochloride. Around 70-75% of the raw material for this product is imported from China. To reduce the exposure and dependence of import, the Company has tied up with domestic suppliers for sourcing raw materials and is also exploring opportunities for backward integration. The Company is confident of reducing the imports to less than 33% over the next three years. Overall. import as a per centage of total raw materials for FY2020 and FY2021 stood at 34% and 42% respectively.

"Bal Pharma has managed to improve its capacity utilization following the easing of Covid related supply chain and logistical issues. With this, the Company is poised to further strengthen its market leading position in diabetes as a therapeutic segment. Bal Pharma's leading product Gliclazide enjoys consistently growing demand from customers across continents, enjoying sizable brand equity in API and formulations. Soon the Company will launch its formulation of Gliclazide MR 30 and 60 mg tablets in the EU market and is expected to file dossier in Q1FY23. While Africa and Latin America remains the dominant market for export formulations, the Company is targeting increasing its presence in various other geographies like Southeast Asia and CIS countries." said Mr. Shailesh Siroya, Managing Director, BAL Pharma.

Shares of Bal Pharma Ltd. was last trading in BSE at Rs. 102.15 as compared to the previous close of Rs. 104.45. The total number of shares traded during the day was 11095 in over 484 trades.

The stock hit an intraday high of Rs. 105.6 and intraday low of 101.5. The net turnover during the day was Rs. 1145865.

Click here to send ur comments or to

Other Headlines:

HCL Technologies Launches HCL SMARTWiFi Platform for Communication Service Providers

Lupin sinks to Q2FY22 consolidated loss of Rs. 2098.04 crores

Larsen & Toubro announces earnings for Q2FY22, H1FY22

Cigniti Recognized as Market Leader in Continuous Testing Specialists for the US by ISG

Sharika Enterprises Ltd receives order worth Rs. 12.33 crore

Now IRCTC 139 Calls are Truecaller Verified

KIMS Hospitals to acquire 51.07% stake in Sunshine Hospitals

Karnataka Bank awarded at the 19th edition of Asia Pacific HRM Congress

Cummins India Limited announces results for Q2 2021-22

Monte Cello BV to Divest Mt Lyell Copper Mine in Australia

Vaibhav Global Ltd reports Rs. 42.18 crore consolidated PAT in Q2 FY22

Happiest Minds Technologies Ltd Q2FY22 consolidated net profit higher at Rs. 44.44 crore

Oracle Financial Services Software Ltd Q2FY22 consolidated net profit at Rs. 447.55 crore

Shriram City Union Finance Ltd reports consolidated PAT of Rs. 298.47 crores in Q2 FY2021-22

ITC Ltd Q2FY22 consolidated PAT rises QoQ, YoY to Rs. 3713.76 crore

MPS Ltd consolidated Q2 FY2021-22 net profit up at Rs. 21.66 crore

KEC International Ltd consolidated Q2FY22 PAT at Rs. 80.29 crore

PNB consolidated Q2FY22 PAT falls QoQ to Rs. 1104.25 crore

Aegis Logistics Ltd consolidated Q2FY22 PAT jumps to Rs. 94.40 crore

MAS Financial Services Ltd Q2FY22 consolidated net profit at Rs. 39.12 crore

Timex Group India Ltd Q2FY22 net profit at Rs. 11.35 crore

Cummins India Ltd Q2FY22 consolidated PAT at Rs. 221.03 crore

Triveni Engineering and Industries Ltd posts consolidated PAT of Rs. 92.47 crore in Q2 FY22

Prerna Infrabuild Ltd Q2FY22 consolidated PAT at Rs. 1.43 crore

Deepak Nitrite Ltd Q2FY22 net profit drops QoQ to Rs. 254.34 crores

IIFL Wealth Management Ltd reports Rs. 142.48 crore consolidated PAT in Q2FY22

HIL Ltd consolidated Q2FY22 PAT declines to Rs. 26.11 crore

Sagar Cements Ltd Q2FY22 consolidated net profit falls to Rs. 21.07 crore

SIS Ltd reports consolidated PAT of Rs. 68.38 crore in Q2FY22

Continental Securities Ltd Q2FY22 net profit up at Rs. 13.44 lakhs

Cosmo Films Ltd reports Rs. 97.30 crores consolidated PAT in Q2 FY2021-22

Ecoboard Industries Ltd posts PAT of Rs. 1.17 crore in Q2 FY2021-22

United Breweries Ltd Q2FY22 consolidated net profit surges to Rs. 80.38 crore

Bajaj Auto Ltd consolidated PAT surges to Rs. 2039.86 crores in Q2FY22

Adani Enterprises Ltd consolidated Q2FY22 net profit slides to Rs. 212.41 crore

Sunil Healthcare Ltd posts consolidated Q2FY22 PAT of Rs. 3.97 lakhs

Dalmia Bharat Ltd reports consolidated net profit of Rs. 204 crore in Q2FY22

IKAB Securities and Investment Ltd Q2FY22 PAT at Rs. 3.05 crore

Share India Securities Ltd Q2FY22 consolidated PAT jumps to Rs. 42.80 crore

Tube Investments of India Ltd posts QoQ, YoY rise in consolidated profit

Balaji Amines Ltd consolidated Q2FY22 PAT slips QoQ to Rs. 79.75 crore

Resonance Specialties Ltd Q2FY22 PAT at Rs. 3.35 crore

KEI Industries Ltd posts consolidated PAT of Rs. 91.70 crore in Q2FY22

Ramco Systems Ltd Q2FY22 consolidated loss at Rs. 12.90 crore

IndusInd Bank Ltd posts consolidated PAT of Rs. 1146.67 crore

Super Sales India Ltd Q2FY22 net profit at Rs. 15.44 crore

Wipro Partners with Micro Focus to Streamline Legacy Apps Migration to Cloud

Triveni Engineering & Industries Ltd Board approves interim dividend of Rs. 1.25

Poonawalla Fincorp Q2FY22 Consolidated Profit Before Tax up 151% YoY to ₹ 126 Cr

Mahindra Logistics Q2 FY22 Revenue at Rs. 1,019 Cr, PAT Rs. 9 Cr

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020